Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?

Osaka University, Suika, Ōsaka, Japan
American Journal of Psychiatry (Impact Factor: 13.56). 05/2005; 162(4):676-82. DOI: 10.1176/appi.ajp.162.4.676
Source: PubMed

ABSTRACT The only approved pharmacological approach for the symptomatic treatment of Alzheimer's disease in Japan is the use of a cholinesterase inhibitor, donepezil hydrochloride. Recent in vivo and in vitro studies raise the possibility that cholinesterase inhibitors can slow the progression of Alzheimer's disease. The purpose of the present study was to determine whether donepezil has a neuroprotective effect in Alzheimer's disease by using the rate of hippocampal atrophy as a surrogate marker of disease progression.
In a prospective cohort study, 54 patients with Alzheimer's disease who received donepezil treatment and 93 control patients with Alzheimer's disease who never received anti-Alzheimer drugs underwent magnetic resonance imaging (MRI) twice at a 1-year interval. The annual rate of hippocampal atrophy of each subject was determined by using an MRI-based volumetric technique. Background characteristics, age, sex, disease duration, education, MRI interval, apolipoprotein E (APOE) genotype, and baseline Alzheimer's Disease Assessment Scale score were comparable between the treated and control groups.
The mean annual rate of hippocampal volume loss among the treated patients (mean=3.82%, SD=2.84%) was significantly smaller than that among the control patients (mean=5.04%, SD=2.54%). Upon analysis of covariance, where those confounding variables (age, sex, disease duration, education, MRI interval, APOE genotype, and baseline Alzheimer's Disease Assessment Scale score) were entered into the model as covariates, the effect of donepezil treatment on hippocampal atrophy remained significant.
Donepezil treatment slows the progression of hippocampal atrophy, suggesting a neuroprotective effect of donepezil in Alzheimer's disease.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD). A double-blind, randomized, placebo-controlled parallel group design using donepezil (10 mg/day) in subjects with suspected prodromal AD. Subjects underwent two brain magnetic resonance imaging scans (baseline and final visit). The primary efficacy outcome was the annualized percentage change (APC) of total hippocampal volume (left + right) measured by an automated segmentation method. Two-hundred and sixteen only subjects were randomized across 28 French expert clinical sites. In the per protocol population (placebo = 92 and donepezil = 82), the donepezil group exhibited a significant reduced rate of hippocampal atrophy (APC = -1.89%) compared with the placebo group (APC = -3.47%), P < .001. There was no significant difference in neuropsychological performance between treatment groups. A 45% reduction of rate of hippocampal atrophy was observed in prodromal AD following 1 year of treatment with donepezil compared with placebo. Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
    Alzheimer's & dementia: the journal of the Alzheimer's Association 01/2015; DOI:10.1016/j.jalz.2014.10.003 · 17.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Methods for the extraction of features from physiological datasets are growing needs as clinical investigations of Alzheimer's disease (AD) in large and heterogeneous population increase. General tools allowing diagnostic regardless of recording sites, such as different hospitals, are essential and if combined to inexpensive non-invasive methods could critically improve mass screening of subjects with AD. In this study, we applied two state of the art multiway array decomposition (MAD) methods to extract unique features from electroencephalograms (EEGs) of AD patients obtained from multiple sites. In comparison to MAD, spectral-spatial average filter (SSFs) of control and AD subjects were used as well as a common blind source separation method, algorithm for multiple unknown signal extraction (AMUSE), and singular value decomposition (SVD) coupled to tensor unfolding. We trained a feed-forward multilayer perceptron (MLP) to validate and optimize AD classification from two independent databases. Using a third EEG dataset, we demonstrated that features extracted from MAD outperformed features obtained from SSFs AMUSE in terms of root mean squared error (RMSE) and reaching up to 100% of accuracy in test condition. We propose that MAD maybe a useful tool to extract features for AD diagnosis offering great generalization across multi-site databases and opening doors to the discovery of new characterization of the disease.
    Journal of neuroscience methods 03/2012; 207(1):41-50. DOI:10.1016/j.jneumeth.2012.03.005 · 1.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Caffeine is the most often used psychoactive substance. Caffeine may influence neuroplasticity in animals. We investigated the relationship between caffeine intake (coffee consumption) and brain morphology. Forty-five healthy, non-smoking women aged 19-30 were included in the present study. We used semi-automatic user-independent MR volumetry and voxel-based morphometry. We investigated the relationship between caffeine intake (coffee consumption) and the volumes of the cortical brain structures where caffeine is supposed to act. We found that high-level and low-level caffeine intake was associated with a larger hippocampus compared to moderate-level caffeine intake. The other brain structures showed no association with coffee consumption or caffeine intake. The U-shape association between caffeine concentration and its effect has already been described in some experimental studies. To our knowledge this is one of the very first studies, which tries to find an association between brain morphology and coffee consumption or caffeine intake in humans using MR imaging.
    Brain Imaging and Behavior 06/2011; 5(4):274-84. DOI:10.1007/s11682-011-9131-6 · 3.39 Impact Factor